184 related articles for article (PubMed ID: 38197630)
21. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter.
Lupey-Green LN; Moquin SA; Martin KA; McDevitt SM; Hulse M; Caruso LB; Pomerantz RT; Miranda JL; Tempera I
Virology; 2017 Jul; 507():220-230. PubMed ID: 28456021
[TBL] [Abstract][Full Text] [Related]
22. Herpes simplex virus type 1 infection activates the Epstein-Barr virus replicative cycle via a CREB-dependent mechanism.
Wu H; Li T; Zeng M; Peng T
Cell Microbiol; 2012 Apr; 14(4):546-59. PubMed ID: 22188237
[TBL] [Abstract][Full Text] [Related]
23. BZLF1 Attenuates Transmission of Inflammatory Paracrine Senescence in Epstein-Barr Virus-Infected Cells by Downregulating Tumor Necrosis Factor Alpha.
Long X; Li Y; Yang M; Huang L; Gong W; Kuang E
J Virol; 2016 Sep; 90(17):7880-93. PubMed ID: 27334596
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
25. Glucocorticoids activate Epstein Barr virus lytic replication through the upregulation of immediate early BZLF1 gene expression.
Yang EV; Webster Marketon JI; Chen M; Lo KW; Kim SJ; Glaser R
Brain Behav Immun; 2010 Oct; 24(7):1089-96. PubMed ID: 20466055
[TBL] [Abstract][Full Text] [Related]
26. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
27. BZLF1 transcript variants in Epstein-Barr virus-positive epithelial cell lines.
Needham J; Adamson AL
Virus Genes; 2019 Dec; 55(6):779-785. PubMed ID: 31552622
[TBL] [Abstract][Full Text] [Related]
28. Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma.
Choi SJ; Ryu E; Lee S; Huh S; Shin YS; Kang BW; Kim JG; Cho H; Kang H
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875759
[No Abstract] [Full Text] [Related]
29. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
30. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.
Feng WH; Westphal E; Mauser A; Raab-Traub N; Gulley ML; Busson P; Kenney SC
J Virol; 2002 Nov; 76(21):10951-9. PubMed ID: 12368338
[TBL] [Abstract][Full Text] [Related]
31. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
32. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells.
Liu S; Li H; Chen L; Yang L; Li L; Tao Y; Li W; Li Z; Liu H; Tang M; Bode AM; Dong Z; Cao Y
Carcinogenesis; 2013 Mar; 34(3):627-37. PubMed ID: 23180656
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
34. Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells.
Hau PM; Deng W; Jia L; Yang J; Tsurumi T; Chiang AK; Huen MS; Tsao SW
J Virol; 2015 Jan; 89(1):652-68. PubMed ID: 25355892
[TBL] [Abstract][Full Text] [Related]
35. The mTOR inhibitor manassantin B reveals a crucial role of mTORC2 signaling in Epstein-Barr virus reactivation.
Wang Q; Zhu N; Hu J; Wang Y; Xu J; Gu Q; Lieberman PM; Yuan Y
J Biol Chem; 2020 May; 295(21):7431-7441. PubMed ID: 32312752
[TBL] [Abstract][Full Text] [Related]
36. Mutant Cellular AP-1 Proteins Promote Expression of a Subset of Epstein-Barr Virus Late Genes in the Absence of Lytic Viral DNA Replication.
Lyons DE; Yu KP; Vander Heiden JA; Heston L; Dittmer DP; El-Guindy A; Miller G
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021895
[TBL] [Abstract][Full Text] [Related]
37. Differentiation-Dependent LMP1 Expression Is Required for Efficient Lytic Epstein-Barr Virus Reactivation in Epithelial Cells.
Nawandar DM; Ohashi M; Djavadian R; Barlow E; Makielski K; Ali A; Lee D; Lambert PF; Johannsen E; Kenney SC
J Virol; 2017 Apr; 91(8):. PubMed ID: 28179525
[TBL] [Abstract][Full Text] [Related]
38. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.
Fahmi H; Cochet C; Hmama Z; Opolon P; Joab I
J Virol; 2000 Jul; 74(13):5810-8. PubMed ID: 10846060
[TBL] [Abstract][Full Text] [Related]
40. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
